

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### ***APPLICATION NUMBER:***

**212209Orig1s000**

***Trade Name:*** VIVIMUSTA injection for intravenous use

***Generic or Proper Name:*** Bendamustine hydrochloride

***Sponsor:*** Slayback Pharma, LLC

***Approval Date:*** December 07, 2022

***Indication:*** VIVIMUSTA is an alkylating drug indicated for treatment of patients with:

- Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

# CENTER FOR DRUG EVALUATION AND RESEARCH

**212209Orig1s000**

## CONTENTS

|                                                           |
|-----------------------------------------------------------|
| <b>Reviews / Information Included in this NDA Review.</b> |
|-----------------------------------------------------------|

|                                                      |          |
|------------------------------------------------------|----------|
| <b>Approval Letter</b>                               | <b>X</b> |
| <b>Other Action Letters</b>                          | <b>X</b> |
| <b>Labeling</b>                                      | <b>X</b> |
| <b>REMS</b>                                          |          |
| <b>Summary Review</b>                                | <b>X</b> |
| <b>Officer/Employee List</b>                         | <b>X</b> |
| <b>Office Director Memo</b>                          |          |
| <b>Cross Discipline Team Leader Review</b>           | <b>X</b> |
| <b>Clinical Review(s)</b>                            | <b>X</b> |
| <b>Product Quality Review(s)</b>                     | <b>X</b> |
| <b>Non-Clinical Review(s)</b>                        | <b>X</b> |
| <b>Statistical Review(s)</b>                         |          |
| <b>Clinical Microbiology / Virology Review(s)</b>    |          |
| <b>Clinical Pharmacology Review(s)</b>               |          |
| <b>Other Reviews</b>                                 | <b>X</b> |
| <b>Risk Assessment and Risk Mitigation Review(s)</b> |          |
| <b>Proprietary Name Review(s)</b>                    | <b>X</b> |
| <b>Administrative/Correspondence Document(s)</b>     |          |

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**212209Orig1s000**

**APPROVAL LETTER**



NDA 212209

**NDA APPROVAL**

Slayback Pharma, LLC  
Attention: Praveen Subbappa  
Senior Director  
301 Carnegie Center, Suite 303  
Princeton, NJ 08540

Dear Mr. Subbappa:

Please refer to your new drug application (NDA) dated and received August 31, 2018, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Vivimusta (bendamustine hydrochloride injection).

We acknowledge receipt of your amendment dated October 7, 2022, following our August 26, 2022, tentative approval letter.

This NDA provides for the use of Vivimusta (bendamustine hydrochloride injection) for treatment of adult patients with:

- Chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling submitted on November 30, 2022, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission **“Final Printed Carton and Container Labeling for approved NDA 212209.”** Approval of this submission by FDA is not required before the labeling is used.

### **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Vivimusta (bendamustine hydrochloride injection) shall be 24 months from the date of manufacture when stored at 2°C to 8°C and protected from light.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-*

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

*Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.*<sup>3</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Patricia Garvey, Lead Regulatory Project Manager, at (301) 796-8493.

Sincerely,

*{See appended electronic signature page}*

Bindu Kanapuru, MD  
Acting Deputy Director  
Division of Hematologic Malignancies II  
Office of Oncologic Diseases  
Office of New Drugs  
Center for Drug Evaluation and Research

**ENCLOSURES:**

- Content of Labeling
  - Prescribing Information
- Carton and Container Labeling

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

BINDU N KANAPURU  
12/07/2022 01:30:18 PM